Product Description
a CD20 Targeting Genome Edited Allogeneic CAR T Therapy; Wholly owned by Precision, PBCAR20A is an allogeneic anti-CD20 CAR T therapy candidate in development for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). (Sourced from: https://investor.precisionbiosciences.com/news-releases/news-release-details/precision-biosciences-announces-fda-clearance-ind-pbcar20a-cd20)
Mechanisms of Action: CAR-T,CD20
Novel Mechanism: Yes
Modality: CAR-T
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Precision BioSciences
Company Location: DURHAM NC 27701
Company CEO: Michael Amoroso
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Lymphoma, Non-Hodgkin|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PBCAR20A-01 | P2 |
Completed |
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2021-06-24 |